Johnson says Evoclence is next generation product

Johnson & Johnson has announced the Food and Drug Administration has decided Evoclence is safe and effective enough to be used to treat moderate to deep facial wrinkles.

As a result, the regulatory body has approved Ortho Dermatologics’ labelling supplement for the product.

Designed to reduce the appearance of folds in the skin, such as nasolabial lines, it is a collagen-based dermal filler.

Johnson & Johnson asserted the treatment represents a “breakthrough” in aesthetics because it is made up of 80 per cent dermis that helps to maintain the strength, structure and support of the skin.

According to the company, the effects are immediate and there is minimal swelling or bruising. This means the product benefits both the physician and consumer by offering more precise wrinkle protection.

The business is confident Evolence will become “a preferred choice within dermal filler options for both aesthetic health professionals and patients”.

Earlier this month, Johnson & Johnson announced it was offering a cash tender to buy all outstanding shares of common stock of Cougar Biotechnology.